To comprehensively analyze and evaluate the multi-dimensional value of acetyl-levo-carnitine, epalrestat and mecobalamin in the treatment of diabetic peripheral neuropathy (DPN), to provide a basis for clinical rational drug use.
The efficacy, safety, cost-effectiveness and innovation of acetyl-levo-carnitine, epalrestat and mecobalamin were comprehensively compared by literature review.
In terms of efficacy, acetyl-levo-carnitine was significantly better than mecobalamin in the median sensory nerve conduction velocity, and it was better than that of mecobalamin in the improvement of pain symptoms. Other efficacy indicators of acetyl-levo-carnitine were similar to mecobalamin and epalrestat. In terms of safety, the incidence of adverse reactions or serious adverse events of acetyl-levo-carnitine, epalrestat and mecobalamin was similar, and all of them were mild adverse reactions. In terms of cost-effectiveness, acetyl-levo-carnitine is more cost-effective than epalrestat and mecobalamin. In terms of innovation, acetyl-levo-carnitine has the dual effects of improving cellular energy metabolism and analgesia in nerve cells.
acetyl-levo-carnitine, epalrestat and mecobalamin have little difference in efficacy and safety. In terms of economy and innovation, acetyl-levo-carnitine has higher value.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |